A replacement is not a last resort. It is a very good operation with a clock on it.

ORTHOBIOLOGICS OR THE OPERATION

This comparison is often framed as a choice, and for most of the conditions on this site it is not one. They sit at different points on a path, and the useful question is which point you are at.

The rule that governs most of it

Biological treatments address biological failure. Surgery addresses structural failure. A tendon that has stopped healing is a biological problem. A tendon that has torn through and retracted is a structural one. No injection reattaches a detached tendon, and no operation makes a degenerate tendon metabolically healthy.

Most disappointment in this field comes from applying one to the other.

Where PRP is the reasonable first move

• Chronic tendinopathy — elbow, patellar, gluteal, plantar fascia — where surgery has modest results and long recoveries
• Knee osteoarthritis at any grade, provided the goal is stated honestly — structural benefit is a reasonable hope in earlier disease, while in advanced disease what is bought is time and a lower medication burden
• Small partial rotator cuff tears with pain out of proportion to structure
• Anyone wanting to defer an operation for a defined reason
• Anyone for whom anesthesia carries meaningful risk

Where surgery is the better answer

• End-stage arthritis with bone-on-bone change and deformity. Hip and knee arthroplasty relieve pain for most people who have them, and that belongs on the scale. So does the other half of the ledger, set out below, which patients are told about far less often.
• Large or retracted full-thickness tendon tears
• Mechanical locking, a bucket-handle meniscal tear, or true instability
• Progressive neurological deficit — weakness or numbness that is worsening
• Fracture, and any suspicion of one

The operations that turned out to do less than assumed

Worth knowing, because they are still commonly offered and because they change how you should weigh a surgical recommendation.

Arthroscopic partial meniscectomy for degenerative tears has been compared against sham surgery in randomized trials, and the results were equivalent. That is a striking finding: the operation performed no better than an incision and an anesthetic. Degenerative meniscal tearing is largely a marker of arthritis rather than a separate fixable lesion.

Subacromial decompression for shoulder impingement has similarly failed to outperform sham in adequately controlled trials.

Vertebroplasty for osteoporotic fractures produced the same pattern in several studies.

The common thread is that all three were widely performed for years on mechanistic reasoning before anyone tested them against a credible control. That history is a reason for humility on all sides, including ours — it is exactly the argument we would make about an over-marketed injection.

Recovery, side by side

PRP: a few days of flare, normal activity within a week, a loading program over three months, and an answer at three to six.

Surgery: anesthesia, a wound, a period of protected weight-bearing or immobilization depending on the procedure, formal rehabilitation over months, and for arthroplasty a recovery measured in six to twelve months before you feel fully settled.

The asymmetry matters in one specific way: PRP does not burn a bridge. If it does not work, surgery remains available on the same terms. The reverse is not true — a replaced joint is replaced.

Using PRP alongside surgery

The application with the more consistent support is not as an alternative but as an adjunct at the time of repair, particularly for rotator cuff healing rates in larger tears. That is a different question from whether it fixes your shoulder without an operation, and the two get conflated in marketing.

How to weigh a surgical recommendation

• What exactly is the operation fixing, and how do you know that is what hurts?
• Has this procedure been compared against a sham or non-operative control in my indication?
• What is the realistic recovery, not the best case?
• What happens if I wait six months — does anything get harder to fix?
• What would you do if it were your knee?

That fourth question is the one that separates a deferrable decision from an urgent one, and it is the question this practice most often helps people answer.

What the operation actually costs

Arthroplasty is presented to most patients as a solved problem, and the implant survival figures encourage that reading. Those figures are real — ten-year implant survival runs at roughly 96% for the knee and 94% for the hip. But implant survival answers a question about the hardware, and the numbers that matter to somebody deciding when to have the operation are different ones.

Four of them carry most of the weight, and they point the same way. Pain does not reliably end: 25% of replaced knees still hurt at a year and 28% at roughly five. Medication does not reliably stop: 21% are still taking opioids twelve months after a knee replacement, 16% after a hip. Recovery is measured in seasons rather than weeks — 18.7% had returned to sport at three months. And the implant is most finite in exactly the people who are told to wait: a joint replaced between the ages of 46 and 50 carries a lifetime revision risk of 22.4% for the knee and 27.6% for the hip, about one in four, with revision a larger operation than the original and a worse one.

The itemized figures, with their caveats and sources, sit on the pages for each joint — what a knee replacement actually costs and what a hip replacement actually costs — because that is where they are useful. What belongs here is what they add up to.

Whose timeline is this

Put those numbers together and the standard advice — have it when the surgeon says you are ready — starts to look like a scheduling decision being made by the wrong person.

The argument for treating a joint biologically in advanced disease is not that it beats an operation. It does not, and this page has already said so. The argument is that it holds a position while the patient decides. It buys time and it lowers the medication burden, and what that time is for is letting somebody have the operation on their own schedule — when work allows it, when there is somebody at home to cover a recovery measured in months, when they have finished trying what they wanted to try first. Or not at all.

Deferring surgery is not automatically a mistake and having it is not automatically a failure. Both are decisions, both belong to the patient, and both are made better with the figures above in hand rather than after them.

What we will tell you

If your hip is bone-on-bone and your life has narrowed to the distance between chairs, we will tell you that a replacement is the operation that changes that, and we will say so even though it means you do not become our patient. If you are not having one — by choice, or because you have been told to wait — then treatment is aimed at the years in between, and we will be honest that time and medication burden are what it buys. If your tendon has been failing for eight months and the proposed operation has no controlled evidence behind it, we will say that too.

A practice that only ever recommends what it sells is not giving you an opinion.

Why “too young for a replacement” is a real problem

Joint replacements have a finite lifespan, and a prosthesis implanted at fifty may need revision, which is a bigger operation with worse outcomes than the original. That is the reasoning behind telling a younger patient to wait, and it is sound reasoning.

What it frequently omits is the cost of the waiting. A decade spent avoiding stairs is a decade of declining quadriceps mass, worsening insulin sensitivity, disrupted sleep and contracting social range. Those are not side effects of the advice — they are the advice’s consequences, and they are rarely entered on the same ledger as the revision risk.

The honest framing is that both options carry a cost and neither is free. What a regenerative approach can legitimately offer in that window is not a cure but a way of making the waiting less destructive: enough function to keep loading the leg, enough sleep to keep inflammatory tone down, enough movement to keep the metabolic picture from sliding. That is a modest claim and it is one we can stand behind.

Two things worth knowing before either decision

Prehabilitation changes surgical outcomes. Strength and metabolic status going into an operation predict how it goes coming out. If surgery is on your horizon in the next year, the work described throughout this site is not an alternative to it — it improves it.

Glycemic control affects both paths. Elevated A1C is associated with higher surgical infection rates and poorer prosthetic outcomes, and with poorer tendon healing after any biological treatment. It is one of the few inputs that improves the odds of every option on the table at once, which is why it gets asked about here regardless of which direction you are heading.

What people ask when surgery is on the table

Can PRP help me avoid a knee replacement?

In earlier disease it may defer one. In end-stage disease it does not substitute for the operation, though it does buy time and reduce what it takes to get through a day. PRP for knee osteoarthritis.

My scan shows a meniscal tear. Do I need surgery?

Degenerative tears performed no better than sham surgery in randomized trials. What we treat.

Can I have PRP after surgery?

Often yes, and it is sometimes used at the time of repair. What to expect.

Does trying PRP first make surgery harder later?

No. It does not burn a bridge. Candidacy.

Related reading

• Still in pain after back surgery
• PRP for knee osteoarthritis
• PRP for hip osteoarthritis
• PRP for rotator cuff tendinopathy
• Am I a candidate?